Clinical implications of aldosterone blockade

American Heart Journal

Volumn 144, Issue 5 SUPPL., 2002, Pages

  Weber, Michael A ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; IRBESARTAN; LOOP DIURETIC AGENT; LOSARTAN; PLACEBO; SPIRONOLACTONE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; BINDING AFFINITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; ETHNIC GROUP; HEART FAILURE; HUMAN; HYPERTENSION; IMPOTENCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEGRO; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RACE DIFFERENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; TARGET ORGAN; TREATMENT OUTCOME;

EID: 0036847542     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2002.129970     Document Type: Conference Paper

References (34)

1. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-65.
2. Duprez D, De Buyzere M, Rietzschel ER, et al. Aldosterone and vascular damage. Curr Hypertens Rep 2000;2:327-34.
3. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993;71:12-6A.
4. Rocha R, Stier CT Jr, Kifor I, et al. Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000;141:3871-8.
5. Barr CS, Lang CC, Hanson J, et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259-65.
6. Yee K-M, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 2001;37:1800-7.
7. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
8. Martin J, Krum H. Eplerenone (GD Searle & Co). Current Opin Invest Drugs 2001;2:521-4.
9. Rabasseda X, Silvestre J, Castañer J. Eplerenone: Antihypertensive, treatment of heart failure, aldosterone antagonist. Drugs Future 1999;24:488-501.
10. McMahon EG. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr Opin Pharmacol 2001;1:190-6.
11. Kannel WB. Blood pressure as a cardiovascular risk factor: Prevention and treatment. JAMA 1996;275:1571-6.
12. Thomas F, Rudnichi A, Bacri A-M, et al. Cardiovascular mortality in hypertensive men according to presence of associated risk factors. Hypertension 2001;37:1256-61.
13. Joffres MR, Hamet P, MacLean DR, et al. Distribution of blood pressure and hypertension in Canada and the United States. Am J Hypertens 2001;14:1099-105.
14. JNC VI. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: 98-4080. Bethesda (Md): National Institutes of Health; 1997.
15. Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control: Results from the Health Survey for England 1998. Hypertension 2001;38:827-32.
16. Lang T, de Gaudemaris R, Chatellier G, et al. Prevalence and therapeutic control of hypertension in 30,000 subjects in the workplace. Hypertension 2001;38:449-54.
17. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995;25:305-13.
18. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2001;24(Suppl 1):S33-43.
19. Julius S, Majahalme S, Palatini P. Antihypertensive treatment of patients with diabetes and hypertension. Am J Hypertens 2001;14:310S-6S.
20. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
21. United States Renal Data System Report, II: Incidence and prevalence of ESRD. Am J Kidney Dis 1999;34(2 Suppl 1):S40-50.
22. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
23. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
24. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. Am J Kidney Dis 2000;36:646-61.
25. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-convertingBenzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
26. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
27. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovasculor outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
28. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men-a comparison of six ontihypertensive agents with placebo. N Engl J Med 1993;328:914-21.
29. Hebert LA, Kusek JW, Greene T, et al. Effects of blood pressure control on progressive renal disease in blacks and whites. Hypertension 1997;30:428-35.
30. Kjeldsen SE, Dahlof B, Devereux RB, et al. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: The LIFE study. Am J Hypertens 2000;13:899-906.
31. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovoscular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.
32. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpaint reduction in hypertension (LIFE) study: A randomised trial against atenolol. Lancet 2002;359:995-1003.
33. Weinberger MH, Roniker B, Krause SL, et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002;15:709-16.
34. Krum H, Nolly H, Workman D, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002;40:117-23.